Fatty acids are essential for survival, acting as bioenergetic substrates, structural
components and signalling molecules. Given their vital role, cells have evolved mechanisms …

Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …

Background European data pre-2019 suggest statin monotherapy is the most common
approach to lipid management for preventing cardiovascular (CV) events, resulting in only …

Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …

Abstract Background and aims This European Atherosclerosis Society (EAS) Task Force
provides practical guidance for combination therapy for elevated low-density lipoprotein …

Many patients do not achieve optimal low-density lipoprotein cholesterol (LDL-C) levels with
statins alone; others are unable to tolerate statin therapy. Additional non-statin treatment …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …

Abstract Purpose of Review The aim of creating an orally active non-statin cholesterol-
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …